LCG
ACAD icon

Lisanti Capital Growth’s Acadia Pharmaceuticals ACAD Stock Holding History

Lisanti Capital Growth’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-81,398
Closed -$3.94M – 111
2020
Q2 		$3.94M Sell
81,398
-6,868
-8% -$330K 0.8% 64
2020
Q1 		$3.73M Sell
88,266
-34,285
-28% -$1.41M 1.23% 28
2019
Q4 		$5.24M Buy
122,551
+15,026
+14% +$654K 1.39% 27
2019
Q3 		$3.87M Buy
107,525
+65,665
+157% +$1.99M 1.26% 31
2019
Q2 		$1.12M Sell
41,860
-64,675
-61% -$1.65M 0.36% 81
2019
Q1 		$2.86M Buy
+106,535
New +$2.49M 1.01% 39
2016
Q3 		– Sell
-12,355
Closed -$401K – 95
2016
Q2 		$401K Sell
12,355
-25,215
-67% -$844K 0.6% 75
2016
Q1 		$1.05M Buy
37,570
+23,277
+163% +$508K 1.24% 32
2015
Q4 		$510K Sell
14,293
-4,892
-25% -$172K 0.54% 75
2015
Q3 		$634K Sell
19,185
-25,291
-57% -$1.05M 0.57% 72
2015
Q2 		$1.86M Sell
44,476
-16,642
-27% -$644K 1.34% 35
2015
Q1 		$1.99M Sell
61,118
-68,673
-53% -$2.36M 1.14% 39
2014
Q4 		$4.12M Buy
129,791
+26,241
+25% +$744K 2.06% 4
2014
Q3 		$2.56M Buy
+103,550
New +$2.42M 1.29% 32
2014
Q1 		– Sell
-38,760
Closed -$969K – 95
2013
Q4 		$969K Sell
38,760
-27,595
-42% -$651K 0.41% 88
2013
Q3 		$1.82M Buy
+66,355
New +$1.39M 0.83% 54

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Lisanti Capital Growth's ACAD Position: Q3 2020 in Review

Lisanti Capital Growth sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 81,398 shares — an estimated $3.94M sold.

Lisanti Capital Growth first reported a position in ACAD in Q3 2013 and held it in 16 quarters. The position peaked at $5.24M in Q4 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Lisanti Capital Growth reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Lisanti Capital Growth sold 81,398 Acadia Pharmaceuticals shares in Q3 2020, an estimated $3.94M.
  • Lisanti Capital Growth first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 16 quarters.
  • Lisanti Capital Growth's Acadia Pharmaceuticals position peaked at $5.24M in Q4 2019.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Lisanti Capital Growth's 13F filing for Q3 2020, filed 5 Nov 2020.